• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Skye Bioscience Inc (OP: SKYE )

    N/A UNCHANGED
    Last Price Updated: 3:57 PM EDT, Apr 10, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Skye Bioscience Inc

    < Previous 1 2 3 Next >
    Skye Bioscience (OTCQB: SKYE) Heads Into 2023 As A Clinical-Stage Company After Dosing Its First Human Participants
    This year has been quite busy for Skye Bioscience Inc. (OTCQB: SKYE). 
    Via Benzinga
    Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE
    San Diego, California--(Newsfile Corp. - December 20, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
    Via Newsfile
    Exposures Product Safety
    Key Marijuana Executive Changes: Who Will Lead MariMed After CEO's Passing? MJBiz CEO Steps Down
    MJBiz CEO To Step Down Marijuana Business Daily's Chris Walsh will step down as CEO in January. 
    Via Benzinga
    Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
    San Diego, California--(Newsfile Corp. - December 16, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
    Via Newsfile
    Skye Bioscience Targets Unmet Needs Of Glaucoma Through Cannabinoids
    Skye Bioscience Inc. was a sponsor at the Benzinga Cannabis Capital Conference on February 25-26, 2021. The information contained in this artic... 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Skye Bioscience Appoints Chris Twitty, PhD, as Chief Scientific Officer
    San Diego, California--(Newsfile Corp. - December 13, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
    Via Newsfile
    Topics Derivatives Intellectual Property
    Exposures Derivatives Intellectual Property
    Skye Bioscience to Present at RHK 2022 Disruptive Growth Conference
    San Diego, California--(Newsfile Corp. - November 22, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
    Via Newsfile
    Skye Bioscience Submits Investigational New Drug Application for SBI-100 Ophthalmic Emulsion to FDA
    San Diego, California--(Newsfile Corp. - November 17, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
    Via Newsfile
    Topics Derivatives
    Exposures Derivatives
    Skye Initiates First-in-Human Phase 1 Clinical Trial For Cannabinoid Based Drug For Treatment Of Glaucoma
    Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has initiated screening for its first-in-human Phase 1 trial... 
    Via Benzinga
    Skye Bioscience Initiates First-in-Human Phase 1 Clinical Trial for SBI-100
    - Recruitment for cohort 1 has begun- ... 
    Via Newsfile
    Skye Bioscience Closes Acquisition of Emerald Health Therapeutics
    San Diego, California--(Newsfile Corp. - November 10, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
    Via Newsfile
    Topics Cannabis
    Exposures Cannabis Product Safety
    Skye Bioscience Stockholders Vote in Favor of Arrangement Agreement with Emerald Health Therapeutics, Inc.
    San Diego, California--(Newsfile Corp. - September 30, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
    Via Newsfile
    Topics Derivatives
    Exposures Derivatives
    Skye One Step Closer To Initiating Clinical Study Of Its Cannabinoid Based Drug For Treatment Of Glaucoma
    Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has been advised by its contract manufacturer that it has... 
    Via Benzinga
    Emerald Health Therapeutics Receives Court Approval of Plan of Arrangement with Skye Bioscience
    Vancouver, British Columbia--(Newsfile Corp. - August 26, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the "Company")... 
    Via Newsfile
    Emerald Health Therapeutics Shareholders Vote in Favour of Plan of Arrangement with Skye Bioscience
    Vancouver, British Columbia--(Newsfile Corp. - August 19, 2022) - Emerald Health Therapeutics, Inc. (CSE: EMH) (OTCQB: EMHTF) ("Emerald" or the... 
    Via Newsfile
    Topics Regulatory Compliance
    Exposures Legal Regulatory
    Easy On The Eyes — This Company Reports Using a Unique Synthetic Cannabinoid Derivative To Treat Glaucoma
    Modern cannabis research reportedly began with Israeli scientists Raphael Mechoulam and Yechiel Gaoni who, in 1964, isolated and identified tetrahydrocannabinol (THC).   Mechoulam later also elucidated... 
    Via Benzinga
    Skye Bioscience Selects NextPharma As Phase 2 Contract Drug Manufacturer
    Skye Bioscience, Inc. (OTCQB: SKYE) , a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has selected NextPharma as its contract manufacturing... 
    Via Benzinga
    Skye Bioscience Receives Australian Ethics Committee Approval to Start First-in-Human Phase 1 Study of SBI-100 Ophthalmic Emulsion
    San Diego, California--(Newsfile Corp. - June 30, 2022) - Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye" or the "Company"), a pharmaceutical... 
    Via Newsfile
    Skye Bioscience Signs Arrangement Agreement With Emerald Health Therapeutics, Here Are The Details
    Skye Bioscience, Inc. (OTCQB: SKYE) and Emerald Health Therapeutics, Inc. 
    Via Benzinga
    Emerald Health Therapeutics Signs Arrangement Agreement with Skye Bioscience
    Arrangement is expected to fund Skye's proprietary synthetic cannabinoid-derivative therapeutic initially targeting glaucoma for first Phase 2 clinical study planned to... 
    Via Newsfile
    Topics Derivatives
    Exposures Derivatives
    Skye Bioscience Shares Up On Keeping Novotech As CRO For Phase 1 Trial Of THC Prodrug Candidate For Glaucoma
    Skye Bioscience, Inc. (OTCQB:SKYE) has entered into... 
    Via Benzinga
    Cannabis Movers & Shakers: Skye Bioscience, The Flowr Corp, Charlotte's Web, Rapid Dose Therapeutics
    Skye Bioscience Announces Board Additions & Promotions CBD-focused biopharmaceutical company Skye Bioscience, Inc. 
    Via Benzinga
    These OTC Securities Had the Most Trading Activity in June
    Photo by Cris Ovalle on Unsplash OTC Markets trading volume was still led by cryptocurrencies and cannabis for the month of June, but many other securities shined comparatively as... 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Watch CV Sciences & Lyphe Group On The Benzinga Cannabis Hour
    Benzinga’s Cannabis Hour is a live show for cannabis investors. On Thursday’s show, hosts Elliot Lane... 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    CEO Presenting on the Emerging Growth Conference on June 9. Register here
    Niche Companies in Technology, Biotech, Precious Metals, and more in Attendance 
    Via EIN Presswire
    Keynotes, Educational Panels and 66 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on April 20-22, 2021
    LOS ANGELES, CA / ACCESSWIRE / April 19, 2021 / The Planet MicroCap Showcase will take place on April 20-22, 2021, where 66 SmallCap, MicroCap and NanoCap public and private companies will be... 
    From Stock News Now
    Via AccessWire
    Topics Cannabis
    Exposures Cannabis
    < Previous 1 2 3 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.